MedTrace Logo

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

NCT00239681 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 17802

Last updated 2014-03-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events.

Conditions

  • Elevated High-sensitivity C-Reactive Protein (hsCRP)

Interventions

DRUG

Rosuvastatin

Oral

OTHER

Placebo

Oral

Sponsors & Collaborators

Principal Investigators

  • Judith Hsia, MD · AstraZeneca

  • Paul Ridker, MD · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States
  • Argentina
  • Belgium
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • Colombia
  • Costa Rica
  • Denmark
  • El Salvador
  • Estonia
  • Germany
  • Israel
  • Mexico
  • Netherlands
  • Norway
  • Panama
  • Poland
  • Puerto Rico
  • Romania
  • Russia
  • South Africa
  • Switzerland
  • United Kingdom
  • Uruguay
  • Venezuela

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00239681 on ClinicalTrials.gov